Pasithea Therapeutics Corp. Stock price

Equities

KTTA

US70261F2020

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
7.25 USD +1.40% Intraday chart for Pasithea Therapeutics Corp. +1.10% -2.02%
Sales 2021 0.02 Sales 2022 0.49 Capitalization 18.77M
Net income 2021 -2M Net income 2022 -13M EV / Sales 2021 -944,383,814 x
Net cash position 2021 52.97M Net cash position 2022 32.22M EV / Sales 2022 -27,645,426 x
P/E ratio 2021
-8.47 x
P/E ratio 2022
-1.16 x
Employees 15
Yield 2021 *
-
Yield 2022
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004 CI
Top Premarket Decliners MT
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position CI
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients MT
Pasithea Therapeutics Gets FDA Acceptance for PAS-004 IND Application DJ
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients CI
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1% MT
Pasithea Therapeutics Gets Positive Response From FDA Meeting for Rare Cancer Treatment DJ
Pasithea Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate CI
Tranche Update on Pasithea Therapeutics Corp.'s Equity Buyback Plan announced on July 20, 2023. CI
Pasithea Therapeutics Corp.'s Equity Buyback announced on July 20, 2023 has expired with 5,323,451 shares, representing 20.36% for $3.73 million. CI
Pasithea Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Pasithea Therapeutics Corp. announces an Equity Buyback for 5,714,285 shares, for $4 million. CI
Pasithea Therapeutics Corp. authorizes a Buyback Plan. CI
More news
1 day+1.40%
1 week+1.10%
Current month-9.37%
1 month-4.60%
3 months-7.05%
6 months-19.53%
Current year-2.02%
More quotes
1 week
7.00
Extreme 7
7.30
1 month
6.70
Extreme 6.7021
8.13
Current year
5.71
Extreme 5.705
8.50
1 year
5.25
Extreme 5.254
17.40
3 years
5.25
Extreme 5.254
170.00
5 years
5.25
Extreme 5.254
170.00
10 years
5.25
Extreme 5.254
170.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 20-07-31
Director of Finance/CFO 46 22-06-30
Corporate Officer/Principal 58 22-05-31
Members of the board TitleAgeSince
Founder 77 19-12-31
Director/Board Member 76 22-09-13
Director/Board Member 58 21-05-31
More insiders
Date Price Change Volume
24-03-28 7.25 +1.40% 1,731
24-03-27 7.15 -2.05% 1,502
24-03-26 7.3 +2.37% 566
24-03-25 7.131 +6.40% 752
24-03-22 6.702 -6.55% 939

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Pasithea Therapeutics Corp. is a biotechnology company. The Company is primarily focused on the discovery, research and development of treatments for Central Nervous System (CNS) disorders and RASopathies. The Company operates through two segments: Therapeutics and Clinics. Its Therapeutics segment performs activities related to the discovery, research, and development of treatments for CNS disorders and other diseases. Its Clinics segment provides business support services to anti-depression clinics in the United Kingdom and in the United States. Its therapeutic pipeline consists of four programs. Its lead product candidate, PAS-004, is a macrocyclic mitogen-activated protein kinase (MEK) inhibitor for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and Noonan syndrome, as well as lamin A/C (LMNA) cardiomyopathy and a number of oncology indications. Its other three programs are in the discovery stage.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Pasithea Therapeutics Corp. - Nasdaq